EDG-6289

EDG-6289 is a discontinued preclinical **small molecule** muscle stabilizer from **Edgewise Therapeutics** that was being developed for rare neuromuscular disorders including Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy. Available source context identifies it as an inhibitor of **myosin light chain, phosphorylatable, fast skeletal muscle**, indicating an intended mechanism focused on modulation of fast skeletal muscle contractile biology to reduce muscle damage and improve muscle stability. Publicly available detail on its exact binding mode, route, formulation, and clinical testing history is limited, and the program appears to have remained in the preclinical stage before being discontinued.